Cannabidiol is under clinical development by Endosane Pharmaceuticals and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs for Schizophrenia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol is under development for the treatment of Schizophrenia. The drug candidate is administered orally as capsule. The drug candidate acts by targeting cannabinoid receptor type 1.
Endosane Pharmaceuticals overview
Endosane Pharmaceuticals (Endosane), a subsidiary of Sanity Group GmbH, develops and commercializes pharmaceutical products for neurological, neuropsychiatric, and psychiatric conditions. The company is investigating cannabinoid-based compounds for the treatment of schizophrenia. It is also evaluating drugs for the treatment of social anxiety disorder, post-traumatic stress disorder and other mental conditions. Endosane approach explores the endocannabinoid system and modulates neurophysiological balance by targeting the underlying pathophysiological mechanisms. The company works in collaboration with the University of California Irvine to develop drugs for post-traumatic stress disorder. Endosane is headquartered in Berlin, Bayern, Germany.
For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.